2007
DOI: 10.1016/j.transci.2006.06.009
|View full text |Cite
|
Sign up to set email alerts
|

World apheresis registry report

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
40
0
2

Year Published

2008
2008
2016
2016

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 43 publications
(46 citation statements)
references
References 5 publications
4
40
0
2
Order By: Relevance
“…In our cohort, there were a few cases of hypotension and hypocalcemia (during citrate anticoagulation), and some rare clotting problems due to high blood viscosity. Similarly low incidences of adverse effects during apheresis procedures are reported from the world apheresis registry, with the exception of hypocalcemia in centers where calcium substitution is not routinely used [27], [28].…”
Section: Discussionsupporting
confidence: 55%
“…In our cohort, there were a few cases of hypotension and hypocalcemia (during citrate anticoagulation), and some rare clotting problems due to high blood viscosity. Similarly low incidences of adverse effects during apheresis procedures are reported from the world apheresis registry, with the exception of hypocalcemia in centers where calcium substitution is not routinely used [27], [28].…”
Section: Discussionsupporting
confidence: 55%
“…Adverse events reported in association with heparin anticoagulation are hemorrhagic in nature, usually at the vascular access site of insertion (0.7%) [21,27,36]. There have been few case reports of heparin-induced thrombocytopenia (HIT) associated with TA procedures, these presented as thrombocytopenia, venous thrombosis, and pulmonary emboli [37].…”
Section: Clinical Adverse Events During Therapeutic Apheresismentioning
confidence: 99%
“…Overall, FFP is associated with a two-fold higher risk of total adverse events relative to albumin, but no difference in treatment interruption has been reported between replacement colloid types [25,27]. In TA procedures FFP is used predominantly for the treatment thrombotic thrombocytopenic purpura (TTP), and FFP replaces the depleted cleaving protease, ADAMTS-13.…”
Section: Clinical Adverse Events During Therapeutic Apheresismentioning
confidence: 99%
See 1 more Smart Citation
“…To understand international perspectives and regional differences, international apheresis registries have been established by the International Society for Apheresis (ISFA) and the World Apheresis Association (WAA) [9][10][11][12][13][14], and more recently, to increase the number of participating centers and to reduce costs, these apheresis registries have been established on the internet [3,[11][12][13][14][15].…”
Section: Introductionmentioning
confidence: 99%